Is tailored therapy feasible in oncology?
- 31 January 2006
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 57 (1) , 79-101
- https://doi.org/10.1016/j.critrevonc.2005.07.003
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryNew England Journal of Medicine, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- A vision for the future of genomics researchNature, 2003
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Metronomic scheduling: the future of chemotherapy?The Lancet Oncology, 2001
- Initial sequencing and analysis of the human genomeNature, 2001